Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up

Cologno, Daniela; d’Onofrio, Florindo; Castriota, O.; Petretta, V.; Casucci, Gerardo; Russo, Antonio; Bussone, Gennaro

doi:10.1007/s10072-013-1384-y

Cited by 14 publications

(7 citation statements)

References 6 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, lamotrigine may primarily reduce vestibular symptoms but headache only to a less extent [ 83 ]. Lamotrigine was also reported useful in three patients with basilar-type migraine over 5 years [ 84 ].…”

Section: Treatmentmentioning

confidence: 99%

Vestibular migraine: the most frequent entity of episodic vertigo

2016

View full text Add to dashboard Cite

Vestibular migraine (VM) is the most common cause of episodic vertigo in adults as well as in children. The diagnostic criteria of the consensus document of the International Bárány Society for Neuro-Otology and the International Headache Society (2012) combine the typical signs and symptoms of migraine with the vestibular symptoms lasting 5 min to 72 h and exclusion criteria. Although VM accounts for 7 % of patients seen in dizziness clinics and 9 % of patients seen in headache clinics it is still underdiagnosed. This review provides an actual overview on the pathophysiology, the clinical characteristics to establish the diagnosis, the differential diagnosis, and the treatment of VM.

show abstract

Section: Treatmentmentioning

confidence: 99%

Vestibular migraine: the most frequent entity of episodic vertigo

2016

View full text Add to dashboard Cite

show abstract

“…The sample included particularly patients who suffered from repeated auras without headache (n = 6), migraine with aphasia during their aura (n = 8), migraine with prolonged aura (>60 minutes, n = 7), basilar‐type migraine (n = 6), or hemiplegic migraine (n = 2). In line, Cologno et al reported in 3 patients having repeated basilar‐type migraine who were treated by LTG at 100 mg/day, a total disappearance of MA attacks over 5 years . The benefit of LTG was also reported in 3 cases of hemiplegic migraine belonging to a family diagnosed with FHM of type 2 and 2 patients with FHM of type 1 .…”

Section: Accumulating Evidence Suggests That Lamotrigine May Reduce Tmentioning

confidence: 61%

Lamotrigine in the Prevention of Migraine With Aura: A Narrative Review

Buch

Chabriat

2019

Headache

View full text Add to dashboard Cite

Background Lamotrigine is not recommended in the prevention of migraine in general but some reports suggest that it might be effective for treating specifically migraine with aura (MA). This review aims to summarize the related data from the literature and to better understand this discrepancy. Methods All reports from the literature related to the use of lamotrigine in migraine with or without aura published prior to February 2019 found using PUBMED and the 2 keywords “migraine” AND “lamotrigine” were reviewed. Original studies, published in full, systematic reviews, and all case reports were synthetized. We also examined the risk profile, pharmacokinetics, and mode of action of lamotrigine in view of the presumed mechanism of MA. Results Lamotrigine was tested in different populations of migraineurs, but previous studies had small sample sizes (n < 35) and might not have been powered enough for detecting a potential benefit of lamotrigine in MA. Accumulating data suggest that the drug can reduce both the frequency and severity of aura symptoms in multiple conditions and is well tolerated. Conclusion Lamotrigine appears promising for treating attacks of MA and related clinical manifestations because of its high potential of efficacy, low‐risk profile, and cost. Additional studies are needed for testing lamotrigine in patients with MA.

show abstract

“…Therefore, lamotrigine appears to mainly act on vestibular symptoms and only to a lesser extent on headaches ( 41 ). Lamotrigine was also effective in three patients with basilar-type migraine over five years ( 42 ).…”

Section: Methodsmentioning

confidence: 99%

Current Treatment Options in Vestibular Migraine

Obermann

Strupp²

2014

Front. Neurol.

View full text Add to dashboard Cite

Approximately 1% of the general population in western industrialized countries suffers from vestibular migraine. However, it remains widely unknown and often under diagnosed despite the recently published diagnostic criteria for vestibular migraine. Treatment trials that specialize on vestibular migraine are scarce and systematic randomized controlled clinical trials are now only emerging. This review summarizes the knowledge on the currently available treatment options that were tested specifically for vestibular migraine and gives an evidence-based, informed treatment recommendation with all its limitations. To date only two randomized controlled treatment trials provide limited evidence for the use of rizatriptan and zolmitriptan for the treatment of vestibular migraine attacks because of methodological shortcomings. There is an ongoing multicenter randomized placebo-controlled trial testing metoprolol 95 mg vs. placebo (PROVEMIG-trial). Therefore, the therapeutic recommendations for the prophylactic treatment of vestibular migraine are currently widely based on the guidelines of migraine with and without aura as well as expert opinion.

show abstract

Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up

Cited by 14 publications

References 6 publications

Vestibular migraine: the most frequent entity of episodic vertigo

Vestibular migraine: the most frequent entity of episodic vertigo

Lamotrigine in the Prevention of Migraine With Aura: A Narrative Review

Current Treatment Options in Vestibular Migraine

Contact Info

Product

Resources

About